Agenus | AGEN - Cost Of Sales


Agenus reported $642K in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Agenus USD 642K 399K Sep/2025
Amgen USD 1.87B 271M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
CSL USD 3.87B 2.08B Dec/2025
Eli Lilly USD 3.27B 309M Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Incyte USD 104.96M 457K Jun/2026
Intrexon USD 1.01M 344K Jun/2024
J&J USD 8.08B 80M Sep/2026
Jiangsu Hengrui CNY 1.02B 68.56M Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Merck EUR 2.27B 199M Jun/2026
Merck USD 3.14B 200M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 4.09B 498M Jun/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Veracyte USD 42.19M 3.7M Jun/2026